Biovista has been selected as one of the top-20 AI Drug Development companies in a recent article in Forbes View the article here: https://www.forbes.com/sites/yiannismouratidis/2018/12/16/the-rising-star-companies-in-ai-drug-development/
Biovista is pleased to announce the signature of a grant agreement within the remit of the EU’s Innovative Medicines Initiative (IMI). Starting in March 2019, the 3.5 year “NeuroDeRisk” project aims to advance the industry’s ability to tackle three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Together with EFPIA members … Read More
By Andreas Persidis, CEO Biovista Inc. The increasing importance of predicting AEs & the role of Augmented Intelligence Case in point: precision medicine and drug repurposing. The approval of a drug has to date been the result of the careful assessment of its benefit-to-risk ratio. In this analysis, the benefit (efficacy) side of the equation … Read More
New Year, new features added to Vizit! The Bibliography pane has been totally revamped: now when you click on a link, a drawer opens up from the right-hand side of the Vizit window with all the supporting bibliography for that link. There are three important changes to the functionality of the bibliography pane: All supporting … Read More
We thought you’d like to know about the new exciting features of the latest release of Biovista Vizit, namely the addition of share to Weibo option and image export support. Biovista Vizit users can now post a graph directly to Sina Weibo. We hope that this new addition to Vizit will better serve our users … Read More